 SAN DIEGO, May 20, 2021 GLOBE NEWSWIRE -- TRACON Pharmaceuticals NASDAQ: TCON, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced the presentation of two abstracts at the upcoming American Society of Clinical Oncology ASCO 2021 annual meeting, being held virtually June 4-8, 2021. 